Ultragenyx Pharmaceutical Inc. Common Stock Earnings Dividend

Ultragenyx Pharmaceutical Inc. Common Stock’s revenue fell -2.36% since last year same period to $136Mn in the Q1 2026. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. Common Stock has generated -34.3% fall in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc. Common Stock’s net profit fell -22.45% since last year same period to $-185Mn in the Q1 2026. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. Common Stock has generated -43.41% fall in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc. Common Stock’s net profit margin fell -25.42% since last year same period to -136.03% in the Q1 2026. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. Common Stock has generated -118.28% fall in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.14 - a 21.92% jump from last quarter’s estimates.

Ultragenyx Pharmaceutical Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.14.

Ultragenyx Pharmaceutical Inc. Common Stock’s earning per share (EPS) jumped 1.91% since last year same period to -1.54 in the Q1 2026. This indicates that the Ultragenyx Pharmaceutical Inc. Common Stock has generated 1.91% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ultragenyx Pharmaceutical Inc. Common Stock’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ultragenyx Pharmaceutical Inc. Common Stock’s return on equity (ROE) stands at -6.08.